CD33 Monoclonal Antibody (HIM3-4), FITC, eBioscience™, Invitrogen™

Description

• Description: The HIM3-4 monoclonal antibody reacts with human CD33, a 67 kDa member of the sialoadhesion family
• CD33 is expressed by myelomonocytic precursors, monocytes, mast cells, and granulocytes
• Hematopoietic stem cells and lymphocytes do not express this antigen
• CD33 plays a role in sialic-acid dependent cell adhesion
• Applications Reported: The HIM3-4 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This HIM3-4 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells
• This can be used at 5 μL (1 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser
• Filtration: 0.2 μm post-manufacturing filtered
• CD33 is a transmembrane protein of the sialic acid-binding immunoglobulin-like lectin (Siglec) family
• It belongs to the immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing molecules able of recruiting protein tyrosine phosphatases SHP-1 and SHP-2 to signal assemblies, and these ITIMs are also used for ubiquitin-mediated removal of the receptor from the cell surface
• CD33 is expressed on cells of myelomonocytic lineage, binds sialic acid residues in N- and O-glycans on cell surfaces, and is a therapeutic target for acute myeloid leukemia
• Further, CD33 is found on granulocyte and macrophage precursors in the bone marrow, but is not on pluripotent stem cells
• CD33 is also expressed on, and is a useful marker for, peripheral monocytes
• CD33 is useful for distinguishing myelogenous leukemia cells from lymphoid or erythroid leukemias
• Diseases associated with CD43 dysfunction include gallbladder lymphoma and extracutaneous mastocytoma.